Quarterly Result31 Oct 2025, 02:37 pm
Dr. Lal PathLabs Reports 10.7% Revenue Growth in Q2 FY26; EBITDA and PAT Increase by 10.8% and 16.4% Respectively
AI Summary
Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider, has announced its financial results for the quarter ended September 30, 2025. The company reported a 10.7% increase in revenue for Q2 FY26 and an 11.0% increase for HF26. EBITDA increased by 10.8% with a margin of 30.7%. PAT increased by 16.4% with a margin of 20.8%. The company also declared an interim dividend of Rs. 7 per share for Q2 FY26. A bonus issue in the ratio of 1:1 has been approved by the board. As of March 31, 2025, the company has 298 clinical laboratories, 6,607 patient service centers, and 12,365 pick-up points.
Key Highlights
- Revenue increased by 10.7% in Q2 FY26 and by 11.0% in HF26
- EBITDA increased by 10.8% with a margin of 30.7%
- PAT increased by 16.4% with a margin of 20.8%
- Interim Dividend of Rs. 7 per share for Q2 FY26
- Board has approved bonus issue in the ratio of 1:1